Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)

The tumor-stroma ratio has previously been shown to be prognostic for patients with invasive breast cancer. We present a validation study to assess the prognostic significance in lymph node-negative, premenopausal patients from the perioperative chemotherapy trial (POP trial, 10854) conducted by the European Organization for Research and Treatment of Cancer. The POP trial assessed the efficacy of one course of perioperative chemotherapy (consisting of fluorouracil, doxorubicin, and cyclophosphamide). Hematoxylin and eosin (H&E) stained sections were retrieved from a subset of premenopausal, node-negative patients from this trial and were scored for the percentage of intra-tumoral stroma. The tumor-stroma ratio was associated with disease-free survival in univariate and multivariate analysis. Tumors with a high tumor-stroma ratio had an increased hazard of 1.853 for disease relapse (95 %CI 1.327–2.585, P < 0.001) independent of other parameters. Combining other parameters with the tumor-stroma ratio improved risk stratification. For triple-negative tumors, the tumor-stroma ratio was associated with an increased hazard for disease relapse, independent of other parameters (HR 2.711, 95 %CI 1.111–6.614, P = 0.028). The tumor-stroma ratio was also independently associated with locoregional recurrence even in breast cancer patients ≤40 years of age (HR 2.201, 95 %CI 1.038–4.669, P = 0.040). This study validates the prognostic value of the tumor-stroma ratio. This parameter can be easily assessed on HE slides and can be implemented next to pathological staging reports to determine patient prognosis.

[1]  M. J. van de Vijver,et al.  Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients , 2004, British Journal of Cancer.

[2]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[3]  S. Paik,et al.  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Delozier,et al.  Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Andrew H. Beck,et al.  Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival , 2011, Science Translational Medicine.

[6]  Hein Putter,et al.  Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients , 2011, Breast Cancer Research and Treatment.

[7]  Xiao-Jun Ma,et al.  Gene expression profiling of the tumor microenvironment during breast cancer progression , 2009, Breast Cancer Research.

[8]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[9]  M J Bissell,et al.  Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. , 1998, The American journal of pathology.

[10]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[11]  H. Putter,et al.  The prognostic role of TGF-β signaling pathway in breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[13]  D. Sgroi,et al.  The molecular pathology of breast cancer progression , 2011, The Journal of pathology.

[14]  R. Rosenfeld,et al.  Cases , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[15]  M. J. van de Vijver,et al.  p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Kristian Pietras,et al.  Hallmarks of cancer: interactions with the tumor stroma. , 2010, Experimental cell research.

[17]  M. Loeffler,et al.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.

[18]  W. McGuire,et al.  Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. , 1992, Annual review of medicine.

[19]  Jason R. Pirone,et al.  Activation of Host Wound Responses in Breast Cancer Microenvironment , 2009, Clinical Cancer Research.

[20]  Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. , 1999 .

[21]  C. Perou,et al.  Interactions with Fibroblasts Are Distinct in Basal-Like and Luminal Breast Cancers , 2010, Molecular Cancer Research.

[22]  H. Tanke,et al.  Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients , 2009, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[23]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[24]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[25]  J. Costantino,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  David Cameron,et al.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.

[28]  Andrew H. Beck,et al.  The fibromatosis signature defines a robust stromal response in breast carcinoma , 2008, Laboratory Investigation.

[29]  W. Mesker,et al.  The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? , 2010, European journal of cancer.

[30]  Melissa A Troester,et al.  Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients , 2012, Breast Cancer Research.

[31]  M. J. van de Vijver,et al.  High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Youn Wha Kim,et al.  Stromal CD10 expression and relationship to the E‐cadherin/β‐catenin complex in breast carcinoma , 2010, Histopathology.

[33]  F. Sotgia,et al.  An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. , 2009, The American journal of pathology.